The 2014 National Institute for Health and Care Excellence (NICE) guidelines for the assessment and management of psoriasis were updated in 2017. There is little of note in relation to the previous articles in this series, however since the development of more biologics and cheaper forms of biosimilars, the guidelines were amended to reflect these readily available treatments (NICE, 2017a). The seventh and final article in this series provides an overview of systemic non-biological and biologic therapies. It looks at how these treatments target and treat psoriasis, as well as side-effects, contraindications and monitoring recommendations of certain drugs.